Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine for Prevention of Radiation-Induced Rectal Toxicity
NCT01586117Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Feb 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in radiation proctitis, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Acute radiation-induced toxicity: daily diarrhea frequency at 3 months. Status: unknown.
02
Drugs
amifostine
03
Conditions
radiation proctitis
Beyond the preview
Go deeper on NCT01586117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01586117.